Lilly Posts Solid Breast Cancer Data, but Pfizer’s Leading Position With Ibrance Remains Intact
Eli Lilly reported strong phase 3 data (Monarch 2) for its CDK4/6 drug abemaciclib in breast cancer, but we continue to believe Pfizer’s Ibrance will dominate the class because of Pfizer’s first-mover advantage and limited differentiating efficacy data from Lilly’s abemaciclib as well as Novartis’ Kisqali. While we see each of these companies as moderately undervalued, Pfizer has the most upside potential, and we continue to believe that Pfizer’s positioning with Ibrance is secure and that Pfize...Pfizer is a research-based biopharmaceutical company. The company is engaged in discovering, developing, manufacturing and distributing of healthcare products, including medicines and vaccines. The company manages its commercial operations through three businesses: Pfizer Biopharmaceuticals Group, which includes Oncology, Inflammation and Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine business units, as well as a hospital business unit; Upjohn, which includes the company's solid oral dose brands such as Lyrica, Lipitor, Norvasc, Celebrex, Viagra, and certain generic medicines; and Consumer Healthcare, which is an over-the-counter medicines business.
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.